Mr. Marc-Andre Massue reports

DIAGNOS: PRIVATE PLACEMENT CLOSING UPDATE

Diagnos Inc. has provided an update to the April 27, 2017, news release on the closing of the private placement with regard to the number of related parties, within the meaning of Multilateral Instrument 61-101, protection of minority securityholders in special transactions, who participated in the private placement.

One director of Diagnos subscribed for $30,000 and one officer of Diagnos subscribed for $10,000; and, as a result thereof, they respectively exercise control over 0.8 per cent and 0.4 per cent of the common shares of the corporation, on a diluted basis. The corporation is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101.

The private placement is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the execution of formal documentation.

About Diagnos Inc.

Founded in 1998, Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its artificial intelligence (AI) tool, CARA (computer-assisted retina analysis). CARA is a cost-effective tool for screening large numbers of patients in real time and has been approved by regulatory authorities (including Health Canada, the U.S. Food and Drug Administration and the European Union) and in Mexico.